Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) Return on Capital Employed (2017 - 2025)

Acro Biomedical has reported Return on Capital Employed over the past 9 years, most recently at 0.39% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.39% for Q4 2025, up 26.0% from a year ago — trailing twelve months through Dec 2025 was 0.39% (up 26.0% YoY), and the annual figure for FY2025 was 0.41%, up 27.0%.
  • Return on Capital Employed for Q4 2025 was 0.39% at Acro Biomedical, up from 0.36% in the prior quarter.
  • Over the last five years, Return on Capital Employed for ACBM hit a ceiling of 7.4% in Q4 2023 and a floor of 622.12% in Q3 2023.
  • Median Return on Capital Employed over the past 5 years was 7.29% (2021), compared with a mean of 41.48%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -60314bps in 2023 and later skyrocketed 59703bps in 2024.
  • Acro Biomedical's Return on Capital Employed stood at 2.68% in 2021, then crashed by -1176bps to 34.17% in 2022, then surged by 122bps to 7.4% in 2023, then crashed by -98bps to 0.13% in 2024, then soared by 202bps to 0.39% in 2025.
  • The last three reported values for Return on Capital Employed were 0.39% (Q4 2025), 0.36% (Q3 2025), and 0.12% (Q2 2025) per Business Quant data.